title: Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy.
abstract: Carvedilol has been shown to improve survival and morbidity in patients with heart failure. It has been demonstrated that carvedilol use is associated with dose-dependent reduction in QT dispersion (QTd) independent of the cause of heart failure, suggesting that reduction in QTd may be a mechanism by which carvedilol improves outcomes in heart failure.
authors.affiliation: Department of Medicine, Division of Cardiology, University of Washington, Seattle 98195-9748, USA.
authors.forename: Basil
authors.initials: B
authors.lastname: Pittenger
authors.forename: Edward A
authors.initials: EA
authors.lastname: Gill
authors.forename: Terry L
authors.initials: TL
authors.lastname: Holcslaw
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bristow
mesh_terms: D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D002227:Carbazoles / Q000008:administration & dosage* / Q000494:pharmacology*; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011412:Propanolamines / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D000317:Adrenergic alpha-Antagonists; D002227:Carbazoles; D010919:Placebos; D011412:Propanolamines; D000077261:Carvedilol